BetterLife Pharma (BETRF) Cash from Investing Activities (2018 - 2021)
BetterLife Pharma (BETRF) posted quarterly Cash from Investing Activities of $1141.1 for Q1 2021, up 100.31% year-over-year from $569.66 in Q1 2020, and down 99.67% quarter-over-quarter from $347807.1 in Q4 2020.
BetterLife Pharma (BETRF) Cash from Investing Activities (2018 - 2021) Analysis & Trends
BetterLife Pharma's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at $1141.1 for Q1 2021.
- In Q1 2021, Cash from Investing Activities rose 100.31% year-over-year to $1141.1; the TTM figure through Jan 2021 stood at -$40463.5 (up 95.32% YoY), while the FY2021 annual figure was -$53526.2, up 93.79% from the prior year.
- Cash from Investing Activities for Q1 2021 stood at $1141.1, down from $347807.1 in the prior quarter.
- The five-year high for Cash from Investing Activities was $347807.1 in Q4 2020, with the low at -$371117.2 in Q1 2020.
- The 4-year median for Cash from Investing Activities is -$246308.7 (2019), against an average of -$154716.8.
- The sharpest annual moves came in 2019 and 2020: Cash from Investing Activities surged 49.14% in 2019, then jumped 309.33% in 2020.
- BetterLife Pharma's Cash from Investing Activities stood at -$326666.0 in 2018, then soared by 49.14% to -$166154.4 in 2019, then surged by 309.33% to $347807.1 in 2020, then slumped by 99.67% to $1141.1 in 2021.
- Business Quant data shows BETRF's Cash from Investing Activities at $1141.1 in Q1 2021, $347807.1 in Q4 2020, and -$326463.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2021 | 1,141.08 |
| Jan 31, 2021 | 1,141.08 |
| Oct 31, 2020 | 347,807.14 |
| Oct 31, 2020 | 347,807.14 |
| Jul 31, 2020 | -326,462.99 |
| Jul 31, 2020 | -326,462.99 |
| Apr 30, 2020 | -62,948.71 |
| Apr 30, 2020 | -62,948.71 |
| Jan 31, 2020 | -371,117.15 |
| Jan 31, 2020 | -371,117.15 |
| Oct 31, 2019 | -166,154.43 |
| Oct 31, 2019 | -166,154.43 |
| Oct 31, 2018 | -326,666.00 |
| Oct 31, 2018 | -326,666.00 |
| Apr 30, 2018 | -333,333.00 |
| Apr 30, 2018 | -333,333.00 |